European Breast Cancer Conference: Focus on Therapy De-escalation and Individualization
An interview with:
Philip Poortmans MD PhD, Radiation Oncology Department, University of Antwerp & Iridium Netwerk, Belgium
BARCELONA, Spain—One of the important themes at the 2026 European Breast Cancer Conference was to individualize therapy for every patient by de-escalating some modalities of treatment in the light of the increasing efficacy of others. The Audio Journal of Oncology sought the opinion of one of Europe’s oncology leaders, Philip Poortmans MD, PhD, researcher at the Iridium Netwerk and the University of Antwerp, in Belgium about findings from the EUROPA trial looking at older patients with early breast cancer, new date on omitting radiation boost to the tumor bed after breast conserving therapy, using axillary radiotherapy in place of axillary node dissection, and the case for watchful waiting in more patients with DCIS.
AUDIO JOURNAL OF ONCOLOGY PODCAST: Philip Poortmans MD PhD
IN: [GOODIN] “Now, Philip Poortmans is …..
OUT: …….of Oncology, I’m Peter Goodwin 11:57secs
Philip Poortmans MD PhD A J Oncology EBCC 2026
